FOLR1 and neoplasm: We used anti-FOLR1 scFv-Fc fusion proteins in an automated, high-plex imaging approach to analyze the respective staining profiles relative to a well-characterized anti-FOLR1 monoclonal antibody, LK26 [38,39], and to assess on-tumor and off-tumor binding on healthy human tissues (adrenal gland, ovary, pancreas, thyroid, cerebellum, cerebrum, lung, spleen, uterus, cervix, breast, placenta, heart, skin, skeletal muscle, kidney, stomach, small intestine, liver, and salivary gland) and malignant human tissues (high grade serous ovarian cancer).